If you could vote on Brexit now which option would you choose?

Sanofi and GSK start test of upgraded coronavirus vaccine after first version disappoints

Sanofi and GlaxoSmithKline on Monday announced the start of a Phase 2 study testing a new version of the experimental coronavirus vaccine the two partners have been developing. The 720-volunteer mid-stage study begins roughly two months after the partners disclosed weaker than expected results for their first vaccine candidate. Sanofi and GSK are evaluating a 'refined antigen formulation' in the new trial, and could start Phase 3 testing in the second quarter if results are positive, they said in a statement. If all goes well, Sanofi and GSK hope to bring a vaccine to market by the fourth quarter of 2021. But that outcome would still represent a six-to-nine month delay from previous estimates, a significant setback for a program that was promised up to $2.1 billion in funding from the U.S. government. Multiple coronavirus vaccines are already available, and others could arrive later this year.

BioPharma Dive - February 22, 2021

View the full story here: https://www.biopharmadive.com/news/sanofi-gsk-upgraded-coronavirus-vaccine-trial/595457/